PepGen Inc. (PEPG)

US — Healthcare Sector

Peers: NKTX ALEC MOLN APLT SAVA CYBN ELTX FATE CRBP CRDF

Automate Your Wheel Strategy on PEPG

With Tiblio's Option Bot, you can configure your own wheel strategy including PEPG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

PEPG
Published: April 16, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

PEPG
Published: April 08, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , April 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

PEPG
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG

PEPG
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG

PEPG
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , March 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG

PEPG
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG

PEPG
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG

PEPG
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls

PEPG
Published: March 04, 2025 by: Benzinga
Sentiment: Negative

On Tuesday, PepGen Inc. PEPG announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the company can review results from the 10 mg/kg cohort.

image for news PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls

2
3
4 (current)

About PepGen Inc. (PEPG)

IPO Date 2022-05-06
Website https://www.pepgen.com
Industry Biotechnology
CEO James G. McArthur
Employees 79

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.